Västra Hamnen: Magle Chemoswed - Looking up
Västra Hamnen Corporate Finance has released a research update on Magle Chemoswed following the company's report for Q2 2021. The PharmaCept acquisition, looming product launches and an improved gross margin combine to justify an increase of our valuation interval to SEK 46.60 - 62.80 per share, writes Västra Hamnen.· CDMO business developing strongly · Impact of PharmaCept acquisition visible in H2 2021 · We raise our valuation interval to SEK 46.60 – 62.80 (42.70 – 57.30) per share Magle Chemoswed reported a net profit of SEK 0.8 million for Q2 2021, almost exactly in line with